Noble Affirms BioCryst Pharma (BCRX) at 'Buy' Following Q4 Results; Two Oral HAE Programs Moving Forward
Tweet Send to a Friend
Noble Financial affirms BioCryst Pharma (Nasdaq: BCRX) with a Buy rating and $8 price target after the company reported quarterly ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
